Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Fanta

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja|August 15, 2009
[No thyroxin dose seemed sufficient--why?]Kalevi Laitinen, Timo Sane, Samuel Fanta
European Journal of Clinical Pharmacology|March 1, 2015
Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosingSamuel Fanta, Mari Kinnunen, Janne T Backman, et al.
Pediatric Nephrology (Berlin, Germany)|March 18, 2005
Cyclosporine A monitoring--how to account for twice and three times daily dosingSamuel Fanta, Janne T Backman, Paula Seikku, et al.
Journal of Clinical Pharmacology|January 29, 2010
Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphismSamuel Fanta, Siv Jönsson, Mats O Karlsson, et al.
Journal of Clinical Pharmacology|May 6, 2011
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporinStefanie Hennig, Joakim Nyberg, Samuel Fanta, et al.
Pharmacogenetics and Genomics|January 15, 2008
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphismsSamuel Fanta, Mikko Niemi, Siv Jönsson, et al.
British Journal of Clinical Pharmacology|March 26, 2013
A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin AAnne-Kristina Frobel, Mats O Karlsson, Janne T Backman, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Duodecim; Laaketieteellinen Aikakauskirja|August 15, 2009
[No thyroxin dose seemed sufficient--why?]Kalevi Laitinen, Timo Sane, Samuel Fanta
European Journal of Clinical Pharmacology|March 1, 2015
Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosingSamuel Fanta, Mari Kinnunen, Janne T Backman, et al.
Pediatric Nephrology (Berlin, Germany)|March 18, 2005
Cyclosporine A monitoring--how to account for twice and three times daily dosingSamuel Fanta, Janne T Backman, Paula Seikku, et al.
Journal of Clinical Pharmacology|January 29, 2010
Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphismSamuel Fanta, Siv Jönsson, Mats O Karlsson, et al.
Journal of Clinical Pharmacology|May 6, 2011
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporinStefanie Hennig, Joakim Nyberg, Samuel Fanta, et al.
Pharmacogenetics and Genomics|January 15, 2008
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphismsSamuel Fanta, Mikko Niemi, Siv Jönsson, et al.
British Journal of Clinical Pharmacology|March 26, 2013
A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin AAnne-Kristina Frobel, Mats O Karlsson, Janne T Backman, et al.
Pageof 1